Building an Early RWE Strategy to Strengthen Market Access, HTA & Reimbursement for High-Cost Rare Disease Therapies
11:00 am - Thursday 11th February 2027
- Explore how early assessment of local patient populations, treatment pathways, unmet need and local healthcare clinical practice can shape an effective RWE and market access strategy
- Examine how conducting local RWD studies ahead of HTA and reimbursement negotiations can provide the evidence needed to understand the evolving treatment landscape and support payer discussions
- Navigate the challenges of generating meaningful RWE in rare diseases where patient populations are small, data availability is limited and HTA:s can vary significantly between markets
